News

Broadway Belts for PFF! raises over $465K for PF this year

The 13th annual Broadway Belts for PFF! gala, put on by the Pulmonary Fibrosis Foundation (PFF), raised more than $465,000 to fight pulmonary fibrosis (PF), a chronic lung disorder thought to affect more than 250,000 U.S. residents. The sold-out event was held earlier this month at Sony Hall…

MSCs may target monocytes, macrophages to reduce fibrosis

Certain populations of immune monocytes and macrophages may be important targets of mesenchymal stem cell (MSC) therapy in idiopathic pulmonary fibrosis (IPF), according to a study. In an IPF mouse model, into-the-vein MSC treatment appeared to prevent monocytes from becoming a type of macrophage thought to promote the buildup…

Haduvio for IPF chronic cough wins new patent in US

Trevi Therapeutics has won approval of its patent application for Haduvio (nalbuphine extended-release tablets), an investigational treatment for chronic cough in people with idiopathic pulmonary fibrosis (IPF). The notice of allowance approving the application was issued on March 7 by the U.S. Patent and Trademark Office. The future…

CIRM awards $1.45M to advance Rubedo’s work on IPF cell therapy

The California Institute for Regenerative Medicine (CIRM) has awarded Rubedo Life Sciences $1.45 million to develop and study a potentially disease-modifying treatment for idiopathic pulmonary fibrosis (IPF) that targets senescent lung stem cells. The funding will enable the biopharmaceutical company to characterize senescent cells —…

First IPF patient dosed in Phase 2 trial of bersiporocin

The first patient has been dosed in a Phase 2 clinical trial of bersiporocin, Daewoong Pharmaceutical’s treatment candidate for idiopathic pulmonary fibrosis (IPF). Full patient dosing and initial data from the study are anticipated by 2024, according to Daewoong. “Daewoong Pharmaceutical has set the significant first step to the…